The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Understanding mechanisms of resistance in myeloma
There are several novel agents and immunotherapies that have changed the treatment landscape of multiple myeloma, yet relapse and disease progression still occur in many patients. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the importance of better understanding mechanisms of resistance to numerous agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), which will be discussed in key sessions at COMy 2022.
